The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II first-in-human trial led by Dana-Farber Cancer Institute and across the country.
This article was originally published on MedicalXpress.com

